National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Baricitinib (Olumiant®) for moderate to severe atopic dermatitis. HTA ID: 20056

Baricitinib (Olumiant®) is indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 14/12/2020
Rapid review completed 28/01/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that baricitinib not be considered for reimbursement at the submitted price*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.